Key result
Chronic rejection limits 5-year survival after lung transplantation to ~50%.
Why the study?
Chronic rejection as obliterative bronchiolitis/bronchiolitis obliterans syndrome limits 5-year survival after lung transplantation, necessitating better understanding of its mechanisms.
Answers are grounded in this paper and cite their sources.
This review summarizes recent advances in the immunobiology and mechanisms of chronic lung allograft dysfunction, a major cause of long-term mortality in lung transplant recipients.
The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.
No takes yet. Share an insight, caveat, or question.
Shilling et al. (2009) conducted a review in Chronic Lung Allograft Dysfunction (Obliterative Bronchiolitis/Bronchiolitis Obliterans Syndrome). Chronic rejection, known as obliterative bronchiolitis or bronchiolitis obliterans syndrome, limits 5-year survival after lung transplantation to approximately 50%.
Synapse has enriched 10 related papers. Consider them for comparative context: